OTC Triptans in New Zealand

July 2013 | 31 pages | ID: O9AACA6A70BEN
Euromonitor International Ltd

Abstracts

During 2012 there were only two OTC triptan products available in New Zealand, Sumagran Active (Mylan New Zealand) and Zomig (AstraZeneca). Several other prescription products were available, such as Maxalt and Arrow-Sumatriptan, however only the latter was subsidised.

Euromonitor International's OTC Triptans in New Zealand report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2008-2012, allowing you to identify the sectors driving growth. Forecasts to 2017 illustrate how the market is set to change.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?

• Get a detailed picture of the OTC Triptans market;
• Pinpoint growth sectors and identify factors driving change;
• Understand the competitive environment, the market’s major players and leading brands;
• Use five-year forecasts to assess how the market is predicted to develop.

Euromonitor International has over 40 years' experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town, Santiago, Sydney, Tokyo and Bangalore and a network of over 800 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.

Contents

Headlines
Trends
Switches
Competitive Landscape
Prospects
Category Data
  Table 1 Sales of OTC Triptans: Value 2007-2012
  Table 2 Sales of OTC Triptans: % Value Growth 2007-2012
  Table 3 OTC Triptans Company Shares by Value 2008-2012
  Table 4 OTC Triptans Brand Shares by Value 2009-2012
  Table 5 Forecast Sales of OTC Triptans: Value 2012-2017
  Table 6 Forecast Sales of OTC Triptans: % Value Growth 2012-2017
Mylan New Zealand Ltd in Consumer Health (new Zealand)
Strategic Direction
Key Facts
Summary 1 Mylan New Zealand Ltd: Key Facts
Summary 2 Mylan New Zealand Ltd: Operational Indicators
Company Background
Production
Competitive Positioning
Summary 3 Mylan New Zealand Ltd: Competitive Position 2012
Executive Summary
Consumer Health Value Sales Increase During 2012
Consumer Focus Shifts Away From Treatment To Prevention
Vitaco Health Ltd Leads New Zealand Consumer Health Industry
Chemists/pharmacies Remain the Most Popular Distribution Channel in 2012
New Zealand Consumer Health Industry To Grow Over the Forecast Period
Key Trends and Developments
New Zealand's Ageing Population Boosts Demand for Consumer Health Products
the Natural Health and Supplementary Products Bill Takes Shape
Public Health Campaigns Drive Growth in Health and Fitness Trends
Tobacco Legislation Impacts Positively on Nrt Smoking Cessation
Natural Healing and Prevention Continues To Be Popular With New Zealand Consumers
Market Indicators
  Table 7 Consumer Expenditure on Health Goods and Medical Services 2007-2012
  Table 8 Life Expectancy at Birth 2007-2012
Market Data
  Table 9 Sales of Consumer Health by Category: Value 2007-2012
  Table 10 Sales of Consumer Health by Category: % Value Growth 2007-2012
  Table 11 Consumer Health Company Shares 2008-2012
  Table 12 Consumer Health Brand Shares 2009-2012
  Table 13 Penetration of Private Label by Category 2007-2012
  Table 14 Sales of Consumer Health by Distribution Format: % Analysis 2007-2012
  Table 15 Sales of Consumer Health by Category and Distribution Format: % Analysis 2012
  Table 16 Forecast Sales of Consumer Health by Category: Value 2012-2017
  Table 17 Forecast Sales of Consumer Health by Category: % Value Growth 2012-2017
Appendix
OTC Registration and Classification
Vitamins and Dietary Supplements Registration and Classification
Self-medication/self-care and Preventative Medicine
Switches
Summary 4 OTC: Switches 2010-2012
Definitions
Sources
Summary 5 Research Sources